

JUL 19 2005

K05-1682

page 1 of 2

2320 N.W. 66TH COURT
GAINESVILLE, FL 32651(352) 377-1140
FAX 352 378-2617**Exactech® AcuMatch 12/14 Press-Fit Femoral Stems****510(k) Summary of Safety and Effectiveness
Special 510(k)**

Sponsor: Exactech® Inc.
2320 N.W. 66th Court
Gainesville, Florida 32653

Phone: (352) - 377 - 1140
Fax: (352) - 378 - 2617

FDA Establishment Number 1038671

Contact: Bennie Gladdish
Hip Systems Manager/Principal Engineer

Date: June 20, 2005

Exactech® AcuMatch 12/14 Press-Fit Femoral Stems**510(k) Summary of Safety and Effectiveness
Special 510(k)****Trade or proprietary or model name(s):**

Exactech 12/14 Alumina Femoral Heads

Information on devices to which substantial equivalence is claimed:

510(k) Number	Trade or Proprietary or Model Name	Manufacturer
#K032964	Exactech 12/14 Alumina Femoral Heads	Exactech, Inc.

INDICATIONS

All Exactech Hip Systems are indicated for use in skeletally mature individuals undergoing primary surgery for hip replacement due to osteoarthritis, rheumatoid arthritis, osteonecrosis, post-traumatic degenerative problems of the hip, and for treatment of proximal femoral fractures where prosthetic replacement is determined by the surgeon as the preferred treatment. Components of Exactech Hip Systems are also potentially indicated for ankylosing spondylitis, congenital hip dysplasia, revision of failed previous reconstructions where sufficient bone stock is present, and to restore mobility resulting from previous fusion.

Special 510(k) Modifications

- Addition of 36 mm outside diameter size femoral head components in three different head lengths (-3.5, 0 +3.5 mm)

Conclusion:

Testing and engineering evaluations were conducted to verify that the performance of the new Exactech AcuMatch 12/14 Press-Fit Femoral Stem components would be adequate for anticipated *in vivo* use. This includes empirical testing and engineering analyses. Based on successful results we conclude that the proposed devices are substantially equivalent to Exactech's predicate femoral stems.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JUL 19 2005

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Maritza Elias
Regulatory Representative
Exactech, Inc.
2320 N.W. 66th Court
Gainesville, Florida 32653

Re: K051682

Trade/Device Name: Exactech 12/14 Alumina Femoral Heads 36 mm

Regulation Number: 21 CFR 888.3353

Regulation Name: Hip joint metal/ceramic/polymer semi-constrained
cemented or nonporous uncemented prosthesis

Regulatory Class: II

Product Code: LZ0

Dated: June 20, 2005

Received: June 23, 2005

Dear Ms. Elias:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Miriam C. Provost', with a stylized flourish at the end.

Miriam C. Provost, Ph.D
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Exactech[®], Inc.

Exactech 12/14 Alumina Femoral Heads 36 mm

Indications for Use

510(k) Number:

K051682

INDICATIONS

All Exactech Hip Systems are indicated for use in skeletally mature individuals undergoing primary surgery for hip replacement due to osteoarthritis, rheumatoid arthritis, osteonecrosis, post-traumatic degenerative problems of the hip, and for treatment of proximal femoral fractures where prosthetic replacement is determined by the surgeon as the preferred treatment. Components of Exactech Hip Systems are also potentially indicated for ankylosing spondylitis, congenital hip dysplasia, revision of failed previous reconstructions where sufficient bone stock is present, and to restore mobility resulting from previous fusion.

CONTRAINDICATIONS

Exactech Hip Systems are contraindicated in patients with active infection, patients without sufficient bone stock to allow appropriate insertion and fixation of the prosthesis, in neuromuscular disorders that do not allow control of the hip joint, and in patients whose weight, age, or activity level would cause the surgeon to expect early failure of the system.

Prescription Use

X


or

Over the Counter Use

No

Please do not write below this line - use another page if needed.

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Revision Sign-Off)

Director, Center for Devices and Radiological Controls
Division of Orthopedic, Prosthetic and Neurological Devices

06/20/05

Number

K051682